Related Experiment Videos
Parenteral meptazinol: a US clinical trial
Postgraduate Medical Journal
|January 1, 1985
Summary
Meptazinol, a mu 1-selective opioid analgesic, offered faster pain relief than morphine but was less potent. Both analgesics showed dose-related side effects, with sleepiness for morphine and nausea for meptazinol.
Area of Science:
- Pharmacology
- Pain Management
- Clinical Trials
Background:
- Cancer patients often experience moderate to severe postoperative pain.
- Effective pain management is crucial for patient recovery and quality of life.
- Opioid analgesics are commonly used, but their efficacy and safety profiles vary.
Purpose of the Study:
- To compare the effectiveness and safety of intramuscular meptazinol with intramuscular morphine in cancer patients.
- To evaluate the potency, onset of action, and side effect profiles of both analgesics.
Main Methods:
- A modified sequential, twin-crossover study design was employed.
- 128 cancer patients with moderate to severe postoperative pain were enrolled.
- Intramuscular meptazinol (50, 100, 200mg) was compared with intramuscular morphine (4, 8, 16mg).
Main Results:
- Meptazinol demonstrated a potency of one-fifteenth to one-twentieth that of morphine.
- Meptazinol provided a more rapid time to peak effect (40 min) compared to morphine (1 h).
- Morphine improved mood, while meptazinol did not. Common side effects included sleepiness with morphine and nausea with meptazinol, both appearing dose-related.
Conclusions:
- Meptazinol is a viable alternative for rapid pain relief in cancer patients, though less potent than morphine.
- Both meptazinol and morphine exhibit dose-dependent side effect profiles.
- Further research may explore optimal dosing strategies and patient-specific responses to these analgesics.